Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY24 results · Apr–Jun 2023
Solara Active Pharma Sciences reported revenue from operations of ₹352.31 crore (up 6.7% from Q1 FY23) and net loss of ₹19.11 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 352.31 | 330.07 | +6.7% | 380.62 | −7.4% |
| Other income | 2.04 | 6.98 | −70.8% | 4.68 | −56.4% |
| Total income | 354.35 | 337.05 | +5.1% | 385.30 | −8.0% |
| Profit before tax | (29.36) | (31.10) | Loss narrowed | 5.04 | Turned loss |
| Net profit for the period | (19.11) | (16.45) | Loss widened | 3.76 | Turned loss |
| Attributable to shareholders of the company | (19.55) | (16.43) | Loss widened | 3.77 | Turned loss |
| EPS, basic (₹) | (5.43) | (4.56) | Loss widened | 1.05 | Turned loss |
| Net margin (%) | -5.4 | -5.0 | 1.0 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 352.31 | 330.07 | +6.7% | 380.62 | −7.4% |
| Other income | 2.07 | 6.48 | −68.1% | 5.12 | −59.6% |
| Total income | 354.38 | 336.55 | +5.3% | 385.74 | −8.1% |
| Profit before tax | (30.13) | (34.39) | Loss narrowed | 8.31 | Turned loss |
| Net profit for the period | (19.88) | (19.18) | Loss widened | 6.46 | Turned loss |
| EPS, basic (₹) | (5.52) | (5.33) | Loss widened | 1.79 | Turned loss |
| Net margin (%) | -5.6 | -5.8 | 1.7 |
Consolidated
- Filed with BSE
- 14 Aug 2023, 15:49 IST
- Board meeting
- 14 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2023, 15:49 IST
- Board meeting
- 14 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE